Contribute Try STAT+ Today

30sep11:00 amA Billion Dollar Decision: To Launch or Out-License in Europe?Virtual Hosted by: Demy-Colton

Hosted by


Event Details

European commercialization can at first sight, appear a little daunting. 30 EAA countries (European Economic Area) plus UK and Switzerland, a population of 370 million, multiple regulatory systems, different reimbursement environments and labor laws, as well as a melting pot of languages and culture. That is why this salon is a must for any CEO considering European commercialization as a strategic option.

With success the rewards of going it alone can be stellar in terms of increased access to your medicines for patients beyond the US and the potential to enhance your market cap exponentially.

The salon draws on the current experience of senior Biotech leaders, highlighting some of the key decision areas including location for the European HQ, timing, phasing and cadence of roll out and perhaps most importantly, the bear traps to avoid!

Sean Morgan-Jones, Chief Commercial Officer, Morgan Prestwich (Moderator)
Barry Greene, CEO, Sage Therapeutics
Stephanie Léouzon, Partner & Head of Torreya Europe
David Meeker, MD, CEO, Rhythm Pharmaceuticals
Anant Murthy, PhD, General Manager, Europe, Argenx


Sep. 30, 11 a.m.-12:15 p.m.